MCK
Fiscal year ends March Quarters are offset from the calendar — Q1 is Apr–Jun

McKesson Corporation is a diversified healthcare services company that distributes pharmaceuticals and medical supplies while providing technology and clinical solutions. The company operates through four main segments: North American Pharmaceutical, which distributes branded, generic, specialty, and over-the-counter drugs to pharmacies, hospitals, and manufacturers in the United States and Canada; Oncology & Multispecialty, which offers specialty drug distribution, infusion services, and supports the U.S. Oncology Network; Prescription Technology Solutions, which provides electronic prior authorization, prescription price transparency, and patient enrollment services; and Medical-Surgical Solutions, which supplies medical-surgical products and laboratory equipment to ambulatory and extended care settings. Key subsidiaries and brands include PRISM Vision, Sarah Cannon Research Institute, Ontada, InspiroGene, and ClarusONE. The company traces its business roots to 1833 and was incorporated in 1994. It partners with biopharma companies, care providers, and governments to deliver healthcare products and services.

Summarised from the company's own disclosures, fiscal year ended May 2026

Industry Medical Distribution Homepage mckesson.com
Sector Healthcare IR page investor.mckesson.com
Tags
pharmaceutical distribution, specialty pharmacy, oncology services, medical-surgical supplies, prescription technology, prior authorization, infusion services, cell and gene therapy, wholesale distribution, healthcare logistics, PRISM Vision, Sarah Cannon Research Institute, Ontada, InspiroGene, ClarusONE, McKesson Connect, Central Fill, McKesson SynerGx, U.S. Oncology Network
Press page —

Metrics

Valuation  
Market cap $ 127.344B
Market cap (USD) $ 127.344B
P/E 28.43
PEG 2.79
P/BV -32.21
P/S 0.30
P/OCF 16.97
P/FCF 17.92
Dividend yield 0.31%
Turnover / mcap —
Returns  
ROE -219.2%
ROI 84.7%
ROIC 90.9%
Profit margin 1.2%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 10.2%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock Yes
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 32
Quality score 31.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000 FY 1999
Revenue 403.43B 359.051B 308.951B 276.711B 263.966B 238.228B 231.051B 214.319B 208.357B 198.533B 190.884B 179.045B 137.609B 122.455B 122.734B 112.084B 108.702B 106.632B 101.703B 92.977B 88.05B 80.515B 69.506B 57.121B 50.006B — — 30.029B
Net profit 4.762B 3.295B 3.002B 3.56B 1.114B -4.539B 900M 34M 67M 5.07B 2.258B 1.476B 1.263B 1.338B 1.403B 1.202B 1.263B 823M 990M 913M 751M -156.7M 646.5M 555.4M 418.6M -48.3M 723.7M 84.9M
Free cash flow 5.719B 5.548B 3.883B 4.769B 4.046B 4.091B 4.012B 3.61B 3.94B 4.34B 3.184B 2.736B 2.862B 2.237B 2.725B 2.105B 2.117B — — — — — — — — — — —

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000 FY 1999
Share price 865.36 672.99 536.85 356.05 306.13 195.04 135.26 117.06 140.87 148.26 157.25 226.2 176.57 107.96 87.77 79.19 65.71 35.03 52.93 59.03 52.1 52.91 — — — — — —
Price performance 12m 0.29 0.25 0.51 0.16 0.57 0.44 0.16 -0.17 -0.05 -0.06 -0.3 0.28 0.64 0.23 0.11 0.21 0.88 -0.34 -0.1 0.13 -0.02 — — — — — — —

Filed figures

Figure Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Balance sheet detail
Trade receivables (USD) 18.2B 17.7B 18.2B 20B 19.2B 18.6B 19.4B 21.6B 25.6B 28B
↳ YoY growth +1.3% -2.8% +3.0% +9.3% -3.9% -3.1% +4.5% +11.4% +18.6% +9.1%
↳ 5y CAGR +12.8% +12.2% +5.2% +4.6% +1.3% +0.4% +1.8% +3.5% +5.1% +7.8%
Borrowings, current (USD) 183M 0.00 330M 1.05B 742M 799M 968M 50M 1.19B 1.27B
Borrowings, non-current (USD) 7.31B 6.75B 7.27B 6.34B 6.41B 5.08B 4.63B 5.58B 4.46B 5.26B
Lease liabilities (USD) — — 2.2B 2.18B 2.49B 1.87B 1.9B 1.95B 1.93B 2.28B
Cash and deposits (USD) 2.78B 2.67B 2.98B 4.02B 6.28B 3.53B 4.68B 4.58B 5.69B 3.98B
Intangible assets (USD) 3.67B 4.1B 3.69B 3.16B 2.88B 2.06B 2.28B 2.11B 1.46B 4.08B
Right-of-use assets (USD) — — 2.1B 1.89B 2.1B 1.55B 1.64B 1.73B 1.78B 2.06B
Net debt (borrowings + leases - cash) (USD) 4.71B 4.08B 4.61B 5.55B 3.36B 4.22B 2.82B 3B 1.89B 4.83B
Cash flow detail
Operating cash flow (USD) 4.74B 4.35B 4.04B 4.37B 4.54B 4.43B 5.16B 4.31B 6.09B 6.16B
Purchases of property, plant and equipment (USD) -404M -405M -426M -362M -451M -388M -390M -431M -537M -436M
Change in receivables (cash effect) (USD) -762M 1.18B -967M -2.49B 1.15B -1.84B -1.08B -2.95B -3.94B -2B
Change in inventories (cash effect) (USD) 320M -458M -368M -376M -2.28B -1.17B -1.26B -1.29B -2.27B -1.08B
Change in payables (cash effect) (USD) 2.07B 271M 1.98B 3.95B 1.27B 2.8B 3.79B 4.59B 8.3B 4.32B
Dividends paid (cash effect) (USD) -253M -262M -292M -294M -276M -277M -292M -314M -345M -381M
Share buybacks (cash effect) (USD) -2.31B -1.71B -1.64B -1.95B -770M -3.52B -3.64B -3.03B -3.15B -4.75B
Interest paid (cash effect) (USD) -315M -298M -383M -235M -220M -186M -224M -234M -273M -212M
Income taxes paid (cash effect) (USD) -587M -144M -262M -368M -379M -359M -562M -901M -1.12B -1.21B
Share-based compensation (USD) 115M 69M 95M 119M 151M 161M 162M 182M 226M 247M
Operating cash flow before change in receivables (USD) 5.51B 3.17B 5B 6.87B 3.4B 6.28B 6.24B 7.27B 10B 8.15B
Free cash flow (OCF - PPE - intangibles) (USD) 4.34B 3.94B 3.61B 4.01B 4.09B 4.05B 4.77B 3.88B 5.55B 5.72B
Income detail
Research and development expense (USD) 341M 125M 71M 96M — — — — — —
↳ 5y CAGR -5.0% -23.6% -31.1% -24.5%
Total comprehensive income (USD) 4.49B 906M 57M 1.27B -4.17B 1.4B 4.4B 3.18B 3.43B 5.29B
Comprehensive income to owners (USD) 4.49B 491M -98M 1.05B -4.32B 1.23B 4.19B 3.03B 3.24B 4.95B
Provision for credit losses (USD) — — — — — 29M 45M 819M -130M 100M
Credit cost ratio (credit losses / average receivables) (%) — — — — — 0.2% 0.2% 4.0% 0.6% 0.4%
Reported May 22, 2017 May 24, 2018 May 12, 2021 May 22, 2020 May 12, 2021 May 8, 2024 May 8, 2024 May 8, 2024 May 9, 2025 May 8, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

McKESSON REPORTS FISCAL 2027 SECOND QUARTER RESULTS AND RAISES FULL YEAR ADJUSTED EPS GUIDANCE IRVING, Texas, November 4, 2026 - McKesson Corporation (NYSE:MCK) today announced results for the second quarter ended September 30, 2026. Second Quarter Highlights: • Consolidated revenues of $111.0 billion increased 8%. • Earnings per diluted share of $10.44 increased $1.52. • Adjusted Earnings per Diluted Share of $11.68 increased 18%. • Generated $3.1 billion of cash flow from operations and $2.9 billion of Free Cash Flow. Fiscal 2027 Full Year Outlook: • Raised Adjusted Earnings per Diluted Share guidance range to $45.60 to $46.40, from the previous range of $44.20 to $45.00. • Fiscal 2027 Adjusted Earnings per Diluted Share guidance range indicates 17% to 19% growth compared to the prior year. • The Company does not forecast GAAP earnings per diluted share1. “McKesson delivered another quarter of strong results, reflecting operational strength in our core business segments and disciplined execution across the enterprise,” said Brian Tyler, chair and chief executive officer. “We continue to invest strategically to advance healthcare outcomes and create long-term value. We further strengthened our portfolio through transactions that will expand our capabilities and deepen our presence in key growth areas, while maintaining our commitment to financial discipline. We are confident in our ability to leverage differentiated solutions and create value for customers, partners, patients, and shareholders. As we close out a strong first half of our fiscal year, I want to thank Team McKesson for their unwavering commitment to excellence and for the impact they make across healthcare every day.” Fiscal 2027 Second Quarter Result Summary Second Quarter ($ in millions, except per share amounts)

Revenues Net income attributable to McKesson Corporation Adjusted Earnings2 Earnings per diluted common share attributable to McKesson Corporation Adjusted Earnings per Diluted Share2

Year-to-Date

FY27 $110,957

FY26 $103,150

% Change 8

FY27 $ 216,337

FY26 $ 200,977

% Change 8

1,218 1,363

1,110 1,227

10 11

1,832 2,546

1,894 2,264

(3) 12

10.44 11.68

8.92 9.86

17 18

15.53 21.59

15.16 18.12

2 19

Second quarter revenues were $111.0 billion, an increase of 8% from a year ago, driven by growth in the North American Pharmaceutical and Oncology & Multispecialty segments due to increased prescription volumes and distribution of specialty products, partially offset by lower contributions from branded pharmaceuticals. Second quarter earnings per diluted share was $10.44 compared to $8.92 a year ago, an increase of $1.52. 1

See below under "Fiscal 2027 Outlook" for full explanation Adjusted results in this earnings release are non-GAAP financial measures; refer to the accompanying definitions and reconciliation schedules

2

Second quarter Adjusted Earnings per Diluted Share was $11.68 compared to $9.86 a year ago, an increase of 18%, driven by strong operational growth across the North American Pharmaceutical, Oncology & Multispecialty, and Prescription Technology Solutions segments, and a lower share count. During the three months ended September 30, 2026, McKesson generated cash from operations of $3.1 billion, and invested $123 million in capital expenditures, resulting in Free Cash Flow of $2.9 billion. During the first six months of the fiscal year, McKesson generated cash from operations of $2.9 billion, and invested $275 million in capital expenditures, resulting in Free Cash Flow of $2.6 billion. For the first six months of the fiscal year, McKesson returned $3.6 billion of cash to shareholders, which included $3.4 billion of common stock repurchases and $198 million of dividend payments. Business Highlights • McKesson signed an agreement to extend its pharmaceutical distribution partnership with CVS Health through June 2032. • On October 5, 2026, McKesson signed a definitive agreement to invest approximately $1.4 billion for a minority interest of approximately 49% in Option Care Health, Inc. This transaction aligns with McKesson’s strategy in supporting the delivery of complex specialty therapies and expanding patient access through community-based care. The transaction is subject to customary closing conditions, including approval by Option Care Health’s stockholders and the receipt of required regulatory approvals. • On November 2, 2026, McKesson completed the acquisition of Precision Medicine Group, LLC, a global provider of clinical research and biopharma commercialization service. This acquisition represents a meaningful milestone in advancing its strategy in oncology, multispecialty, and biopharma services. • On November 2, 2026, PRISM Vision Group expanded its network with the addition of Spectrum Vision Partners, adding more than 150 providers and bringing its total provider network to more than 350. North American Pharmaceutical Segment • Revenues were $91.4 billion, an increase of 6%, driven by increased prescription transaction volumes, including higher volumes from specialty products to health systems and strategic accounts, partially offset by lower contributions from branded pharmaceuticals. • Segment Operating Profit was $1.1 billion. Adjusted Segment Operating Profit was $1.0 billion, an increase of 22%, driven by growth in the distribution of specialty products to health systems and strategic accounts. Oncology & Multispecialty Segment • Revenues were $15.0 billion, an increase of 24%, driven by growth in provider solutions and specialty distribution. • Segment Operating Profit was $352 million. Adjusted Segment Operating Profit was $427 million, an increase of 8%, driven by growth in provider solutions and specialty distribution. Prescription Technology Solutions Segment • Revenues were $1.5 billion, an increase of 10%, driven by increased prescription volumes in third-party logistics and access solutions, partially offset by lower contributions from hub dispensing services. • Segment Operating Profit was $275 million. Adjusted Segment Operating Profit was $307 million, an increase of 18%, driven by higher demand for access solutions.

Medical-Surgical Solutions Segment • Revenues were $3.1 billion, an increase of 5%, driven by growth across the extended and ambulatory care channels. • Segment Operating Profit was $164 million. Adjusted Segment Operating Profit was $225 million, a decrease of 10%, driven by lower contributions from the ambulatory care channel due to product mix, partially offset by growth in the extended care channel. Fiscal 2027 Outlook McKesson does not provide forward-looking guidance on a GAAP basis as the company is unable to provide a quantitative reconciliation of forward-looking Non-GAAP measures to the most directly comparable forward-looking GAAP measure, without unreasonable effort. McKesson cannot reasonably forecast LIFO inventory-related adjustments, certain litigation loss and gain contingencies, transaction related expenses and adjustments, restructuring, impairment and related charges, and other adjustments, which are difficult to predict and estimate. These items are generally uncertain and depend on various factors, many of which are beyond the company's control, and as such, any associated estimate and its impact on GAAP performance could vary materially. McKesson is raising its fiscal 2027 Adjusted Earnings per Diluted Share guidance to $45.60 to $46.40 from the previous range of $44.20 to $45.00. “The raise in fiscal 2027 Adjusted Earnings per Diluted Share guidance is underpinned by the strength in our business and the confidence we have in our ability to execute consistently,” said Kenny Cheung, executive vice president and chief financial officer. “We are committed to building towards the future through disciplined capital deployment and strategic investments.” Additional modeling considerations will be provided in the earnings call presentation. Conference Call Details McKesson has scheduled a conference call for today, Wednesday, November 4, 2026, at 4:30 PM ET to discuss the company’s financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website at investor.mckesson.com. Upcoming Investor Events McKesson management will participate in the following investor events: • Jefferies Global Healthcare Conference, November 17, 2026 • Evercore Healthcare Conference, December 1, 2026 • J.P. Morgan Healthcare Conference, January 11-14, 2027 A complete listing of public events open to the investment community will be available on McKesson's Investor Relations website, including details, updates, and a link to each webcast. Non-GAAP Financial Measures GAAP refers to the U.S. generally accepted accounting principles. This press release includes GAAP financial measures as well as Non-GAAP financial measures, including Adjusted Gross Profit, Adjusted Operating Expenses, Adjusted Other Income, Adjusted Interest Expense, Adjusted Income Tax Expense, Adjusted Earnings, Adjusted Earnings per Diluted Share, Adjusted Segment Operating Profit, Adjusted Segment Operating Profit Margin, Adjusted Corporate Expenses, Adjusted Operating Profit, and Free Cash Flow which are financial measures not calculated in accordance with GAAP. Refer to the “Supplemental NonGAAP Financial Information” section of the accompanying financial statement tables for the definitions and usefulness of the company’s Non-GAAP financial measures and the attached schedules for reconciliations of the differences between the Non-GAAP financial measures and their most directly comparable GAAP financial measures.

Cautionary Statements This earnings release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by their use of terminology such as “believes,” “expects,” “anticipates,” “may,” “will,” “should,” “seeks,” “approximately,” “intends,” “projects,” “plans,” “estimates,” “targets,” or the negative of these words or other comparable terminology. Any discussion of our intent to separate our Medical-Surgical Solutions segment into an independent company, other anticipated or completed transactions, including the anticipated closings thereof, or synergies expected therefrom, litigation outcomes, financial outlook, guidance, trends, strategy, plans, assumptions, expectations, commitments, and intentions may also include forward-looking statements. Forward-looking statements are not representations of historical or current facts or circumstances and they involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, anticipated, or implied. Readers should not place undue reliance on forward-looking statements, such as financial performance forecasts, which speak only as of the date they are first made. Except to the extent required by federal securities laws, we undertake no obligation to publicly release the result of any revisions to any forward-looking statements to reflect events or circumstances after the date the statements are made, or to reflect the occurrence of unanticipated events. Although it is not possible to predict or identify all such risks and uncertainties, we encourage investors to read the risk factors described in our publicly available filings with the Securities and Exchange Commission and news releases. These risk factors include, but are not limited to: our planned separation of Medical-Surgical Solutions and the closing of our investment in Option Care Health, Inc., each of which is subject to conditions, may not be completed on the currently contemplated terms or timeline, or at all, and, if completed, may not achieve the intended financial and strategic benefits; we experience costly and disruptive legal disputes and settlements, including regarding our role in distributing controlled substances such as opioids; we experience losses not covered by insurance or indemnification; we are subject to frequently changing, extensive, complex, and challenging healthcare and other laws and policies; we from time to time record significant charges from impairment to goodwill, intangibles, and other long-lived assets; we experience cybersecurity incidents that might significantly compromise our technology systems or might result in material data breaches; we experience significant problems with information systems or networks; the adoption and use of artificial intelligence in our business operations exposes us to risks and uncertainties; we may be unsuccessful in achieving our strategic growth objectives; we may be unsuccessful in our efforts to implement initiatives to reduce or optimize our costs; we might be unable to successfully complete or integrate acquisitions or other strategic transactions, especially in the timeframes noted; we may not receive anticipated benefits from acquisitions or other strategic transactions; we might be adversely impacted by delays or other difficulties with divestitures; we are impacted by customer purchase reductions, contract non-renewals, payment defaults, and bankruptcies; our contracts with government entities involve future funding, payment, and compliance risks; we might be harmed by changes in our relationships or contracts with suppliers; our use of third-party data is subject to risks and limitations that could impede the growth of our data services business; we might be unable to successfully recruit and retain qualified employees; we might be adversely impacted by healthcare reform such as changes in pricing and reimbursement models; we might be adversely impacted by competition and industry consolidation; we are adversely impacted by changes or disruptions in product supply and have difficulties in sourcing or selling products due to a variety of causes; we are adversely impacted as a result of our distribution of generic pharmaceuticals; we are adversely impacted by changes in the economic environments in which we operate; changes affecting capital and credit markets might impede access to credit, increase borrowing costs, and disrupt banking services for us and our customers and suppliers and might impair the financial soundness of our customers and suppliers; we might be adversely impacted by changes in tax legislation or challenges to our tax positions; and we might be adversely impacted by conditions and events outside of our control, such as widespread public health issues, natural disasters, and geopolitical factors.

About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read Stories & Insights. We routinely use our website, investor.mckesson.com, to post information that may be material to investors, such as business developments, earnings, and financial performance, as well as presentation materials and details for upcoming and past events.

NEWS RELEASE

McKesson Corporation Declares Quarterly Dividend 2026-10-21 IRVING, Texas--(BUSINESS WIRE)-- The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 94 cents per share of common stock. The dividend will be payable on January 4, 2027, to shareholders of record on December 1, 2026.

About McKesson Corporation McKesson Corporation is a diversi ed healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and a ordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read Stories & Insights. We routinely use our website, investor.mckesson.com, to post information that may be material to investors, such as business developments, earnings, and nancial performance, as well as presentation materials and details for upcoming and past events. Investors [email protected] Media Relations [email protected] Source: McKesson Corporation

1

NEWS RELEASE

CD&R and McKesson Corporation Sign Agreement to Acquire Option Care Health 2026-10-06 NEW YORK & IRVING, Texas & BANNOCKBURN, Ill.--(BUSINESS WIRE)-- CD&R, McKesson Corporation (NYSE: MCK) (“McKesson”), and Option Care Health, Inc. (Nasdaq: OPCH) (“Option Care Health”) announced today that they have entered into a de nitive agreement, under which CD&R and McKesson will acquire Option Care Health, an independent provider of home and alternate site infusion services, for $32.05 per share, re ecting a total enterprise value of approximately $5.8 billion. At the closing of the transaction, CD&R will hold a majority ownership interest, and McKesson will hold a minority ownership interest. Option Care Health will remain a separate company led by its own management team. “We are pleased to have entered into this agreement, which provides immediate cash value for our stockholders,” said Harry Kraemer, Chairman of the Board of Option Care Health. “The Board of Directors completed an extensive assessment, involving thorough discussions with our advisors, and unanimously concluded this transaction maximizes value for our stockholders.” “This transaction represents a great outcome for Option Care Health and our stockholders, and I want to thank our Board of Directors for their rigorous process and diligence,” said John C. Rademacher, Chief Executive O cer of Option Care Health. “For more than 45 years, Option Care Health has helped transform the way infusion therapy is delivered, led by our team members’ unwavering commitment to providing extraordinary care to patients. We will continue to enhance our platform and deepen our partnerships with hospitals and health systems, physicians, payers, and biopharma manufacturers. We are thrilled to have the support of CD&R and McKesson, empowering us to continue investing strategically and accelerate the pace of our advanced technology deployment to improve clinical outcomes and reduce the total cost of care. Both rms understand our business and the healthcare industry, and have proven track records of fostering growth for some of the largest and fastest-growing healthcare service businesses globally.” 1

“Option Care Health has shown what is possible when high-quality infusion therapy is delivered where patients are most comfortable: at home and in their communities,” said CD&R Partner Sarah Kim. “We look forward to supporting Option Care Health’s proven management team, together with McKesson and applying CD&R’s deep experience in healthcare services to help Option Care Health bring specialized therapies to more patients across the country.” “This investment represents an important opportunity that aligns with McKesson’s long-term strategy to expand access and a ordability to innovative therapies across the care continuum,” said Brian Tyler, Chair and Chief Executive O cer of McKesson. “As these therapies continue to grow in importance and their delivery becomes increasingly complex, McKesson is focused on investing in areas where our capabilities can help improve access and advance care in lower-cost community settings, at or closer to home. Option Care Health’s clinical model and national infusion footprint across home and ambulatory sites are well aligned with those priorities, and the company is well positioned for continued growth. As a strategic investor, we look forward to bringing McKesson’s experience and expertise in specialty pharmaceuticals to support Option Care Health’s strategy of broadening access to complex therapies and enabling care delivery in lower-cost settings, while creating long-term value for stakeholders.” The transaction aligns with McKesson’s strategic objectives: Positioned for growth in specialty care: Continued innovation in specialty, rare and orphan therapies and the increasing need for alternate infusion services represent an attractive long-term growth opportunity to support community providers, health systems, payers, and biopharma companies. Through this investment, McKesson will support the delivery of complex specialty therapies across multiple care settings. Expanded patient access through community-based care: Option Care Health’s home and ambulatory infusion capabilities help patients access complex therapies outside traditional care settings, aligning with McKesson’s focus to allow accessible and a ordable high-quality care to patients. Option Care Health will continue to operate as usual, with the same commitment to its patients, providers, employees, and partners.

Transaction Details, Timing, and Approvals Under the de nitive agreement, CD&R will hold a majority interest of approximately 51% in Option Care Health and McKesson will invest approximately $1.4 billion for a minority interest of approximately 49%. The transaction also establishes a framework for McKesson’s future acquisition of CD&R’s interest in Option Care Health, subject to speci ed conditions and regulatory approvals. Following the closing of the transaction, McKesson intends to account for its minority interest in Option Care Health using the equity method of accounting, recording its share of 2

Option Care Health’s net income or loss in Other Income, net. The transaction value represents a premium of approximately 37% to Option Care Health’s closing share price on October 5, 2026, the last full trading day of Option Care Health’s common stock prior to the transaction announcement. The transaction is expected to close in the rst half of calendar year 2027, subject to customary closing conditions, including approval by Option Care Health’s stockholders and the receipt of required regulatory approvals. Upon completion of the transaction, Option Care Health’s common stock will no longer be publicly listed on the Nasdaq Stock Exchange, and Option Care Health will become a privately held company.

Option Care Health Third Quarter 2026 Financial Results and 2026 Guidance Option Care Health expects to release its nancial results for the third quarter ended September 30, 2026, on November 4, 2026. Given the transaction announcement, Option Care Health will not host a live conference call in conjunction with its third quarter earnings release and is also withdrawing its previously disclosed nancial guidance.

Advisors Centerview Partners LLC is serving as nancial advisor, Kirkland & Ellis LLP is serving as legal advisor, and Joele Frank, Wilkinson Brimmer Katcher is serving as strategic communications advisor to Option Care Health. BofA Securities, Barclays, Goldman Sachs, Je eries, and Wells Fargo are acting as nancial advisors on this transaction and are also providing committed nancing to the consortium. Debevoise & Plimpton LLP is serving as legal advisor to CD&R. Davis Polk & Wardwell LLP and Reed Smith LLP are serving as McKesson’s legal advisors.

About Option Care Health Option Care Health is the nation’s largest independent provider of home and alternate site infusion services. With over 8,000 team members including more than 5,000 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and team members. To learn more, please visit our website at optioncarehealth.com.

About CD&R Founded in 1978, CD&R is a leading private investment rm with a strategy of generating strong investment returns 3

by building more robust and sustainable businesses through the combination of skilled investment experience and deep operating capabilities. In partnership with the management teams of its portfolio companies, CD&R takes a long-term view of value creation and emphasizes positive stewardship and impact. The rm invests in businesses that span a broad range of industries, including industrial, healthcare, consumer, technology and nancial services end markets. CD&R is privately owned by its partners and has o ces in New York and London. For more information, please visit www.cdr.com and follow the rm’s activities through LinkedIn.

About McKesson Corporation McKesson Corporation is a diversi ed healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and a ordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read Stories & Insights. We routinely use our website, investor.mckesson.com, to post information that may be material to investors, such as business developments, earnings, and nancial performance, as well as presentation materials and details for upcoming and past events.

Additional Information and Where to Find It In connection with the proposed acquisition and related transactions (collectively, the “proposed transaction”) involving Option Care Health and a liates of CD&R and McKesson (collectively, the “Investor Group”), Option Care Health will le a preliminary proxy statement with the U.S. Securities and Exchange Commission (the “SEC”). Option Care Health plans to mail a de nitive proxy statement (the “Proxy Statement”) to Option Care Health’s stockholders. OPTION CARE HEALTH’S STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders will be able to obtain a free copy of the Proxy Statement (when available) as well as other documents led by Option Care Health with the SEC through the website maintained by the SEC at www.sec.gov. Copies of the documents led with the SEC by Option Care Health will be available free of charge on Option Care Health’s internet website at optioncarehealth.com or by contacting Option Care Health’s investor relations department at [email protected].

Certain Information Regarding Participants in the Solicitation 4

Option Care Health and its directors and executive o cers may be considered participants in the solicitation of proxies from Option Care Health’s stockholders in connection with the proposed transaction. Information about the directors and executive o cers of Option Care Health is set forth in its proxy statement for its 2026 annual meeting of stockholders, which was led with the SEC on April 8, 2026 (the “Annual Meeting Proxy Statement”). To the extent the holdings of Option Care Health’s securities by its directors or executive o cers have changed since the amounts set forth in the Annual Meeting Proxy Statement, such changes have been or will be re ected on Forms 3, 4 and 5 led with the SEC. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, in the proposed transaction will be contained in the proxy statement that Option Care Health expects to le and in other relevant materials to be led with the SEC regarding the proposed transaction when they become available. You may obtain these documents (when they become available) as described above.

Cautionary Statement Regarding Forward-Looking Statements - Option Care Health This communication may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identi ed by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements include statements regarding the proposed transaction, stockholder approval and the expected bene ts of and timeline for completing the proposed transaction. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management’s beliefs, expectations and assumptions at the time that these statements were prepared. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are di cult to predict and many of which are outside of Option Care Health’s control. Option Care Health’s actual results and nancial condition may di er materially from those indicated in the forward-looking statements as a result of various factors. These factors include, but are not limited to: (1) the termination of or occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement, including circumstances requiring Option Care Health to pay a termination fee pursuant to the merger agreement, or the inability to complete the proposed transaction on the anticipated terms and timetable, (2) the inability to complete the proposed transaction due to the failure to obtain approval of the stockholders of Option Care Health or to satisfy any other condition to closing in a timely manner or at all, or the risk that a regulatory approval that may be required for the proposed transaction is delayed, is not obtained or is obtained subject to conditions that are not anticipated, (3) costs related to the proposed transaction, including from 5

potential litigation relating to the proposed transaction, (4) the risk that restrictions on the operation of Option Care Health’s business during the pendency of the proposed transaction may impact Option Care Health’s ability to pursue certain business opportunities or strategic transactions or undertake certain actions Option Care Health might otherwise have taken, (5) the risk that any announcements relating to the proposed transaction could have adverse e ects on the market price of Option Care Health’s common stock, credit ratings or operating results, (6) the risk that the proposed transaction and its announcement could have an adverse e ect on the ability of Option Care Health to retain and hire key personnel, retain customers and maintain relationships with business partners, suppliers and customers and (7) the diversion of management’s time and attention from ordinary course business operations to completion of the proposed transaction. The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included elsewhere. Additional information concerning risks, uncertainties and assumptions can be found in Option Care Health’s lings with the SEC, including the risk factors discussed in Option Care Health’s most recent Annual Report on Form 10-K, as updated by Option Care Health’s Quarterly Reports on Form 10-Q and future lings with the SEC. Any forward-looking statement made in this communication is based only on information currently available to Option Care Health and speaks only as of the date on which it is made. Option Care Health undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. You are cautioned not to rely on Option Care Health’s forward-looking statements.

Cautionary Statements - McKesson Corporation Except for historical information, statements in this press release regarding McKesson’s proposed minority investment in Option Care Health, the proposed acquisition of Option Care Health by the CD&R-controlled investment vehicle and related arrangements constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that involve risks and uncertainties that could cause actual results to di er materially from those in those statements. It is not possible to identify all such risks and uncertainties. The reader should not place undue reliance on forward-looking statements, which speak only as of the date they are rst made. Except to the extent required by law, McKesson undertakes no obligation to publicly update forward-looking statements. We encourage investors to read the important risk factors described in McKesson’s publicly available lings with the Securities and Exchange Commission. These risks include, but are not limited to: the parties may be unable to obtain required stockholder or regulatory approvals or satisfy other closing conditions; the transaction may be delayed or may not be completed; McKesson may not achieve the expected bene ts of its investment; Option Care Health may not achieve the expected growth or other outcomes described in this release; McKesson may record impairment or other charges relating to its investment; and the parties’ ownership structure may adversely a ect the transaction, 6

industry relationships or the businesses involved.

Option Care Health Investors Bob Okunski [email protected] Media Relations Sharon Stern / Arielle Rothstein / Allison Sobel Joele Frank, Wilkinson Brimmer Katcher (212) 355-4449

CD&R External A airs Jon Selib [email protected]

McKesson Corporation Investors [email protected] Media Relations [email protected] Source: McKesson Corporation and CD&R and Option Care Health, Inc.

7

Prompts

McKesson Corporation (ticker MCK), listed in United States.

Company History

Date Change Detail
Feb 6, 2013 Acquired Acquired Pss World Medical Inc (CIK 920527). Its filings from before the deal are on its own company page, not shown here.
Nov 5, 2010 Acquired Acquired US Oncology Inc (CIK 943061). Its filings from before the deal are on its own company page, not shown here.
Nov 8, 2006 Acquired Acquired Per SE Technologies Inc (CIK 878556). Its filings from before the deal are on its own company page, not shown here.
Jan 25, 2000 Renamed MCKESSON CORP → MCKESSON HBOC INC

ETFs Holding McKesson Corporation

ETF Weight in ETF Shares Market value As of
EGGS 6.12% 2,656 $ 2.935M Nov 17, 2026
SEMG 6.02% 3,394 $ 3.71M Nov 18, 2026
CWS 5.51% 5,591 $ 6.104M Nov 17, 2026
FCTE 5.02% 16,226 $ 12.26M Jun 30, 2026
CTEF 4.95% 26,474 $ 28.9M Nov 18, 2026
EASY 4.41% 3,136 $ 2.685M Jul 31, 2026
KAT 4.14% 35,623 $ 26.917M Jun 30, 2026
NEWZ 4.08% 778 $ 850K Nov 18, 2026
MFUT 3.86% 2,611 $ 2.885M Nov 17, 2026
DVGR 3.73% 572 $ 620K Nov 18, 2026
GRW 3.54% 2,683 $ 2.297M Jul 31, 2026
STNC 3.48% 3,775 $ 3.232M Jul 31, 2026
HCOW 2.70% 583 $ 440.515K Jun 30, 2026
BDIV 2.42% 189 $ 161.82K Jul 31, 2026
SELV 2.34% 7,601 $ 5.743M Jun 30, 2026
CLCV 2.22% 444 $ 380.148K Jul 31, 2026
SPCT 2.15% 1,687 $ 1.444M Jul 31, 2026
WBIF 2.05% 637 $ 481.317K Jun 30, 2026
LCAP 2.04% 49,329 $ 37.273M Jun 30, 2026
JHAC 2.03% 95 $ 71.782K Jun 30, 2026
CLCG 2.02% 668 $ 571.935K Jul 31, 2026
GDIV 2.00% 4,453 $ 4.911M Nov 13, 2026
CPAI 1.94% 9,447 $ 7.138M Jun 30, 2026
LOWV 1.91% 4,401 $ 3.896M Aug 31, 2026
HRTS 1.88% 1,182 $ 1.046M Aug 31, 2026
ABFL 1.85% 11,375 $ 9.739M Jul 31, 2026
MFSV 1.79% 12,121 $ 10.731M Aug 31, 2026
PVAL 1.72% 273,908 $ 242.496M Aug 31, 2026
WBIG 1.58% 575 $ 434.47K Jun 30, 2026
TFPN 1.49% 2,073 $ 2.291M Nov 17, 2026
TMED 1.46% 444 $ 335.486K Jun 30, 2026
FMAG 1.39% 3,989 $ 3.415M Jul 31, 2026
AVIE 1.35% 203 $ 224.323K Nov 16, 2026
ROE 1.34% 3,041 $ 3.32M Nov 18, 2026
YNOT 1.27% 2,799 $ 2.478M Aug 31, 2026
UPSD 1.24% 1,694 $ 1.45M Jul 31, 2026
BUSA 1.15% 4,558 $ 3.444M Jun 30, 2026
SFGV 1.14% 12,054 $ 13.16M Nov 18, 2026
SURE 1.13% 593 $ 647.36K Nov 17, 2026
TAX 1.01% 289 $ 255.857K Aug 31, 2026
REGS 1.01% 866 $ 654.35K Jun 30, 2026
DSTL 0.98% 27,631 $ 20.878M Jun 30, 2026
VAMO 0.97% 1,235 $ 1.057M Jul 31, 2026
SEIV 0.94% 18,299 $ 13.827M Jun 30, 2026
MEDI 0.90% 363 $ 390.969K Nov 12, 2026
LSEQ 0.90% 142 $ 156.599K Nov 13, 2026
FTLS 0.88% 20,696 $ 0.00 Nov 16, 2026
BDYN 0.86% 23,494 $ 25.962M Nov 16, 2026
TCAL 0.73% 2,186 $ 2.416M Nov 17, 2026
SMIZ 0.72% 2,236 $ 1.98M Aug 31, 2026
INFO 0.70% 5,668 $ 6.251M Nov 13, 2026
NDOW 0.66% 604 $ 456.382K Jun 30, 2026
CLSE 0.64% 6,538 $ 5.788M Aug 31, 2026
VFMV 0.60% 3,088 $ 2.734M Aug 31, 2026
BDVL 0.57% 9,210 $ 10.177M Nov 16, 2026
BALI 0.57% 7,955 $ 8.791M Nov 16, 2026
TGRT 0.53% 7,736 $ 8.549M Nov 17, 2026
VFMF 0.53% 5,863 $ 5.191M Aug 31, 2026
ACLC 0.52% 1,920 $ 1.7M Aug 31, 2026
BAMG 0.49% 711 $ 629.463K Aug 31, 2026
SIXL 0.49% 951 $ 1.024M Nov 12, 2026
CAPE 0.42% 1,337 $ 1.01M Jun 30, 2026
VSLU 0.41% 2,980 $ 2.252M Jun 30, 2026
BTAL 0.41% 1,518 $ 1.147M Jun 30, 2026
GQI 0.38% 1,307 $ 987.569K Jun 30, 2026
TVAL 0.34% 3,534 $ 3.905M Nov 17, 2026
LCTU 0.34% 3,482 $ 3.848M Nov 16, 2026
ACVF 0.32% 575 $ 492.309K Jul 31, 2026
ABCS 0.30% 43 $ 38.069K Aug 31, 2026
XMAG 0.29% 584 $ 628.997K Nov 13, 2026
INRO 0.29% 1,544 $ 1.706M Nov 16, 2026
SFTY 0.27% 2,440 $ 2.16M Aug 31, 2026
STOX 0.27% 687 $ 608.215K Aug 31, 2026
THEQ 0.27% 89 $ 98.349K Nov 17, 2026
VFVA 0.27% 2,924 $ 2.589M Aug 31, 2026
FLDZ 0.26% 14 $ 10.578K Jun 30, 2026
AFLG 0.25% 2,073 $ 2.291M Nov 16, 2026
THRO 0.24% 22,958 $ 25.37M Nov 16, 2026
DFSU 0.23% 5,198 $ 5.599M Nov 12, 2026
DYNF 0.23% 86,264 $ 95.325M Nov 16, 2026
ENHU 0.20% 17 $ 18.786K Nov 16, 2026
LGDX 0.20% 242 $ 267.42K Nov 17, 2026
AAUS 0.20% 953 $ 1.04M Nov 18, 2026
MODL 0.19% 2,626 $ 1.984M Jun 30, 2026
NBCR 0.19% 1,840 $ 1.629M Aug 31, 2026
JUSA 0.19% 1,558 $ 1.701M Nov 17, 2026
BRCE 0.19% 79 $ 69.94K Aug 31, 2026
DFUS 0.18% 36,411 $ 39.216M Nov 12, 2026
ACIO 0.17% 4,727 $ 4.047M Jul 31, 2026
ADME 0.16% 561 $ 480.323K Jul 31, 2026
GDE 0.16% 864 $ 764.916K Aug 31, 2026
APUE 0.16% 4,435 $ 3.926M Aug 31, 2026
TACU 0.15% 25 $ 27.626K Nov 17, 2026
DFAU 0.14% 17,388 $ 18.728M Nov 12, 2026
NTSD 0.14% 68 $ 51.381K Jun 30, 2026
NTSX 0.14% 2,598 $ 1.963M Jun 30, 2026
DCOR 0.14% 60,177 $ 64.814M Nov 12, 2026
AVSU 0.14% 619 $ 684.02K Nov 16, 2026
VOXP 0.13% 9 $ 7,705.71 Jul 31, 2026
HCMT 0.13% 836 $ 715.775K Jul 31, 2026